Open AccessALK INHIBITORS AND POSSIBLE SMALL MOLECULES OF NON-SMALL CELL LUNG CANCER: A LITERATURE REVIEW
Author(s) -
Utpalendu Paul,
Subhadeep Banerjee
Publication year - 2020
Publication title -
international journal of engineering applied science and technology
Language(s) - English
Resource type - Journals
ISSN - 2455-2143
DOI - 10.33564/ijeast.2020.v05i08.024
Subject(s) - anaplastic lymphoma kinase , lung cancer , small molecule , cancer research , carcinogenesis , medicine , cancer , oncology , drug discovery , bioinformatics , biology , genetics , malignant pleural effusion
Lung cancer is among the deadliest cancers forhumans and makes up about 13% of all diagnosed cancer.NSCLC, which accounts for 85% of all lung cancer isepithelial lung cancer and consists of four stages. Manyproteins can cause NSCLC, among them is AnaplasticLymphoma Kinase (ALK). ALK-EML-4 fusion formcauses tumorigenesis. Patients with NSCLC having EML4-ALK gene rearrangements are not associated withethnicity, smoking or sex. According to this factor, manyavailable small molecules have been developed which caninhibit ALK and therefore decreases the progression ofNSCLC in patients but certain limitations of these drugshave led to the discovery of more potent small molecules.Treatment with small molecules has provided effectiveclinical benefit with very little toxicity. This study aims atfinding potent small molecules using BindingDB accordingto their IC50 values to overcome the resistance of preexisting drug molecules.